Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

MYGN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Myriad Genetics Inc.

accessnewswire.com
MYGN The article details a law firm's investigation into Myriad Genetics due to potential securities law violations. The company reported a significant decline in Q2 revenue, reduced full-year guidance, and a substantial drop in stock price following these announcements. Factors like lower reimbursement and payer friction were cited.

MYGN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Myriad Genetics Inc. NEW YORK CITY, NY / ACCESS Newswire / August 18, 2026 / ( ACCESS NEWSWIRE)-The law firm of Kirby McInerney LLP continues its investigation on behalf of Myriad Genetics Inc. ("Myriad Genetics" or the "Company") (NASDAQ:MYGN) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices.

[ CONTACT THE FIRM IF YOU SUFFERED A LOSS]

What Happened?

On July 30, 2026, Myriad Genetics reported that its second-quarter revenue declined 11% year-over-year to 190.7 million and average revenue per test declined 9%. The Company reduced its full-year 2026 revenue guidance to $770 to 790 million and revealed an $11 million reduction in revenue due to changes in collection estimates for tests completed in prior periods. Additionally, Myriad reported that hereditary cancer testing revenue declined 13%, despite an 8% increase in volume, attributing the decline to lower reimbursement and unfavorable estimate changes associated primarily with first-quarter 2026 orders. Management stated that payer-generated revenue-cycle friction was "not new" and identified changing prior-authorization requirements, increased medical-record requests, and higher denial rates. Management acknowledged that the Company "should have engaged earlier and more directly with payers as conditions evolved" and that earlier intervention "could have reduced the downstream impact." On this news, Myriad's stock price declined by $2.51, or 47%, to close at $2.86 on July 31, 2026.

What Should I Do?

At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws.

If you purchased or otherwise acquired Myriad Genetics securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

[LEARN MORE ABOUT SECURITIES CLASS ACTIONS]

Kirby McInerney LLP is a New York-based plaintiffs' law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm's efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP's website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP

Lauren Molinaro, Esq.

212-699-1171

https://www.kmllp.com

https://securitiesleadplaintiff.com/

[email protected]

SOURCE: Kirby McInerney LLP